Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | HTR3A | P46098 | 4/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071892 | 0.90 | ELANE (0.53) | CNR1CNR2HTR3AHTR4CYP3A4 | |
| SCHEMBL17324730 | 0.88 | CNR1 (0.48) | CNR1CNR2HTR3AHTR4REN | |
| SCHEMBL2808445 | 0.88 | ELANE (0.49) | CNR1CNR2HTR3AF2PLAU | |
| SCHEMBL15882396 | 0.86 | ELANE (0.58) | CNR1CNR2F2PLAUELANE | |
| SCHEMBL15882017 | 0.86 | CNR1 (0.50) | CNR1CNR2CYP3A4 | |
| SCHEMBL20250798 | 0.84 | CNR1 (0.49) | CNR1CNR2HTR3AHTR4REN | |
| SCHEMBL17321441 | 0.82 | CNR1 (0.51) | CNR1CNR2HTR3AHTR4REN | |
| SCHEMBL31429292 | 0.82 | ELANE (0.56) | CNR1CNR2HTR3AF2PLAU | |
| SCHEMBL17324818 | 0.80 | KDM4C (0.50) | CNR1CNR2HTR3AELANEALDH1A1 | |
| SCHEMBL27795771 | 0.79 | ELANE (0.44) | CNR1CNR2HTR3AF2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |